GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaxis Ltd (OTCPK:PXSLY) » Definitions » Gross-Profit-to-Asset %

Pharmaxis (Pharmaxis) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Pharmaxis Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Pharmaxis's annualized Gross Profit for the quarter that ended in Dec. 2023 was $0.00 Mil. Pharmaxis's average Total Assets over the quarter that ended in Dec. 2023 was $12.67 Mil. Therefore, Pharmaxis's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.


Pharmaxis Gross-Profit-to-Asset % Historical Data

The historical data trend for Pharmaxis's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaxis Gross-Profit-to-Asset % Chart

Pharmaxis Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.64 15.90 20.38 24.06 12.14

Pharmaxis Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.14 25.63 2.10 20.10 -

Competitive Comparison of Pharmaxis's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmaxis's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaxis's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmaxis's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Pharmaxis's Gross-Profit-to-Asset % falls into.



Pharmaxis Gross-Profit-to-Asset % Calculation

Pharmaxis's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=2.053/( (17.699+16.125)/ 2 )
=2.053/16.912
=12.14 %

Pharmaxis's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (16.125+9.207)/ 2 )
=0/12.666
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Pharmaxis Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Pharmaxis's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaxis (Pharmaxis) Business Description

Traded in Other Exchanges
Address
20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.

Pharmaxis (Pharmaxis) Headlines